Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Moskowitz, Craig H
[Clear All Filters]
2024
Driessen J
,
de Wit F
,
Herrera AF
,
Zinzani PLuigi
,
Lacasce AS
,
Cole PD
,
Moskowitz CH
,
Garcia-Sanz R
,
Fuchs M
,
Mueller H
, et al.
Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis.
Blood Adv. 2024.
PubMed
Google Scholar
2023
Armand P
,
Zinzani PLuigi
,
Lee HJu
,
Johnson NA
,
Brice P
,
Radford J
,
Ribrag V
,
Molin D
,
Vassilakopoulos TP
,
Tomita A
, et al.
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma.
Blood. 2023.
PubMed
Google Scholar
Epstein-Peterson ZD
,
Drill E
,
Aypar U
,
Batlevi CLee
,
Caron P
,
Dogan A
,
Drullinsky P
,
Gerecitano J
,
Hamlin PA
,
Ho C
, et al.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica. 2023.
PubMed
Google Scholar
2020
Zinzani PLuigi
,
Chen R
,
Armand P
,
Johnson NA
,
Brice P
,
Radford J
,
Ribrag V
,
Molin D
,
Vassilakopoulos TP
,
Tomita A
, et al.
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis.
Leuk Lymphoma. 2020:1-5.
PubMed
Google Scholar
2018
Vardhana S
,
Hamlin PA
,
Yang J
,
Zelenetz A
,
Sauter CS
,
Matasar MJ
,
Ni A
,
Yahalom J
,
Moskowitz CH
.
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B-cell Lymphoma Treated with Second-line Therapy and Intent to Transplant.
Biol Blood Marrow Transplant. 2018.
PubMed
Google Scholar
2015
Moskowitz CH
.
Analysis of primary-refractory Hodgkin lymphoma pts in a randomized, placebo-controlled study of brentuximab vedotin consolidation after autologous stem cell transplant.
Clin Adv Hematol Oncol. 2015;13 Suppl 9(8):14-15.
PubMed
Google Scholar
Moskowitz CH
,
Nademanee A
,
Masszi T
,
Agura E
,
Holowiecki J
,
Abidi MH
,
Chen AI
,
Stiff P
,
Gianni AM
,
Carella A
, et al.
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2015.
PubMed
Google Scholar
Ulaner GA
,
Goldman DA
,
Sauter CS
,
Migliacci J
,
Lilienstein J
,
Gönen M
,
Schöder H
,
Moskowitz CH
,
Zelenetz AD
.
Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.
Radiology. 2015:142556.
PubMed
Google Scholar